NCT06299111: An ongoing trial by Regeneron Pharmaceuticals
This trial is ongoing. It must report results 9 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06299111 |
|---|---|
| Title | A Master Protocol for a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies Against Factor XI for Prevention of Venous Thromboembolism in Patients With a Peripherally Inserted Central Catheter (ROXI-CATH) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 20, 2024 |
| Completion date | March 27, 2026 |
| Required reporting date | March 27, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 3, 2026 |
| Days late | None |